RT Journal Article
T1 Nanomedicines for pulmonary drug delivery: overcoming barriers in the treatment of respiratory infections and lung cancer
A1 Fernandez Garcia, Raquel
A1 Fraguas Sánchez, Ana Isabel
AB The pulmonary route for drug administration has garnered a great deal of attention in therapeutics for treating respiratory disorders. It allows for the delivery of drugs directly to the lungs and, consequently, the maintenance of high concentrations at the action site and a reduction in systemic adverse effects compared to other routes, such as oral or intravenous. Nevertheless, the pulmonary administration of drugs is challenging, as the respiratory system tries to eliminate inhaled particles, being the main responsible mucociliary escalator. Nanomedicines represent a primary strategy to overcome the limitations of this route as they can be engineered to prolong pulmonary retention and avoid their clearance while reducing drug systemic distribution and, consequently, systemic adverse effects. This review analyses the use of pulmonary-administered nanomedicines to treat infectious diseases affecting the respiratory system and lung carcinoma, two pathologies that represent major health threats.
PB MDPI
YR 2024
FD 2024-10-11
LK https://hdl.handle.net/20.500.14352/132302
UL https://hdl.handle.net/20.500.14352/132302
LA eng
NO Fernández-García R, Fraguas-Sánchez AI. Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer. Pharmaceutics [Internet]. 11 de diciembre de 2024 [citado 13 de febrero de 2026];16(12):1584. Disponible en: https://www.mdpi.com/1999-4923/16/12/1584
DS Docta Complutense
RD 27 feb 2026